Bristol Myers Squibb entered two separate research collaboration and licensing deals, one with San Francisco-based SyntheX and the second with London’s Autolus Therapeutics.
https://www.pharmalive.com/wp-content/uploads/2022/10/BioSpaceBMS10-4-2022.jpg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-10-04 12:03:002022-10-04 12:03:00BMS invests in protein degradation, cell therapy platforms
